Floris A. de Jong

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

Andrea Wang‐Gillam, Richard Hubner, Jens T. Siveke et al. · European Journal of Cancer · 2019 · 299 citations · Full text

ABCG2 Pharmacogenetics

Floris A. de Jong, Sharon Marsh, Ron H.J. Mathijssen et al. · Clinical Cancer Research · 2004 · 206 citations

Flat-Fixed Dosing Versus Body Surface Area–Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?

Ron H.J. Mathijssen, Floris A. de Jong, Walter J. Loos et al. · The Oncologist · 2007 · 142 citations · Full text

Drug Safety, Therapeutic Drug Monitoring, Oncology +12

Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia

Jessica M. van der Bol, Ron H.J. Mathijssen, Walter J. Loos et al. · Journal of Clinical Oncology · 2007 · 126 citations · Full text

Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes

Ron H.J. Mathijssen, Floris A. de Jong, Ron H. N. van Schaik et al. · JNCI Journal of the National Cancer Institute · 2004 · 124 citations · Full text